Sign In
Buy XPHYF
$0.284
+0 (+0%)
At Close: Apr 17, 2023
BioNxt Solutions Announces Closing of Shares for Debt Settlement
09:45pm, Friday, 19'th Sep 2025
VANCOUVER, BC / ACCESS Newswire / September 19, 2025 / BioNxt Solutions Inc. ("BioNxt" or the "Company") (CSE:BNXT)(OTCQB:XPHYF)(FSE:4XT) is pleased to announce that, further to its news release of Se
Semaglutide API Delivery Enables Start of Lab-Scale ODF Development at BioNxt
03:05am, Tuesday, 02'nd Sep 2025
VANCOUVER, BC / ACCESS Newswire / September 2, 2025 / BioNxt Solutions Inc. ("BioNxt" or the "Company") (CSE:BNXT)(OTC PINK:XPHYF)(FSE:4XT) is pleased to announce the receipt of the Semaglutide active
BioNxt's Sublingual Cladribine Program for MS Ready for Next Phase
03:05am, Monday, 07'th Jul 2025
VANCOUVER, BC / ACCESS Newswire / July 7, 2025 / BioNxt Solutions Inc. ("BioNxt" or the "Company") (CSE:BNXT)(OTC:XPHYF)(FSE:4XT), a bioscience innovator specializing in advanced drug delivery systems
Bionxt Solutions Provides Bi-Weekly MCTO Status Report
07:30pm, Thursday, 15'th May 2025
VANCOUVER, BC / ACCESS Newswire / May 15, 2025 / BioNxt Solutions Inc. ("BioNxt" or the "Company") (CSE:BNXT)(OTC PINK:XPHYF)(FSE:4XT), announces that, further to its news release dated May 1, 2025 (t
BioNxt Solutions Announces Closing of Second Tranche of Non-Brokered Private Placement
07:00pm, Wednesday, 19'th Jun 2024
NOT FOR DISTRIBUTION TO UNITED STATES NEWS WIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES VANCOUVER, BC / ACCESSWIRE / June 19, 2024 / BioNxt Solutions Inc. ("BioNxt" or the "Company") (CSE:B
BioNxt Solutions Announces Closing of Third and Final Tranche of Non-Brokered Private Placement
06:20pm, Friday, 27'th Oct 2023
NOT FOR DISTRIBUTION TO UNITED STATES NEWS WIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES VANCOUVER, BC / ACCESSWIRE / October 27, 2023 / BioNxt Solutions Inc. ("BioNxt" or the "Company") (CS
BioNxt Solutions Announces Change of Directors
04:30pm, Tuesday, 03'rd Oct 2023
VANCOUVER, BC / ACCESSWIRE / October 3, 2023 / BioNxt Solutions Inc. ("BioNxt" or the "Company") (CSE:BNXT)(OTCQB:XPHYF)(FSE:4XT), announces that Per Thoresen and Peter Damouni have resigned as direct
XPhyto Therapeutics Corp has announced that its director and founder Professor Dr Raimar Loebenberg is the 2022 recipient of the Canadian Society for Pharmaceutical Sciences (CSPS) Award of Leadershi
XPhyto Therapeutics Corp has announced that Dr Florian A. Sahr, a German-born and internationally-trained leader in drug formulation, technology transfer and new-product manufacturing, has joined its
XPhyto Therapeutics advancing Rotigotine transdermal patch towards final pivotal study in fourth quarter this year
08:00am, Monday, 04'th Apr 2022
XPhyto Therapeutics Corp has updated on the progress of its Rotigotine transdermal (TDS) patch product candidate, which is a non-ergoline dopamine agonist approved to treat Parkinson's disease (PD) a
XPhyto Therapeutics makes strong progress on its psychedelic medicine programs and novel compounds
08:21am, Tuesday, 22'nd Feb 2022
XPhyto Therapeutics Corp. (CSE:XPHY, OTCQB:XPHYF) gave investors an update on the strong progress made by its wholly owned subsidiary XPhyto Laboratories Inc's psychedelic medicine programs in Canada'
XPhyto Therapeutics planning to release strategy on psychedelic medicine program in days as it updates on business divisions
08:10am, Tuesday, 08'th Feb 2022
XPhyto Therapeutics Corp. (CSE:XPHY, OTCQB:XPHYF) told investors that it plans to update on its strategy for its psychedelic medicine program in coming days as the group reported on progress at its th
XPhyto Therapeutics realizing 'significant synergies' after integration of 3a-diagnostics GmbH
08:07am, Monday, 24'th Jan 2022
XPhyto Therapeutics Corp. (CSE:XPHY, OTCQB:XPHYF) told investors that its successful integration of 3a-diagnostics GmbH (3a), an acquisition, which closed in December last year, was already bearing fr
XPhyto Therapeutics announces appointment of Drahoslav Zdarek as the company's head of sales, Europe
07:55am, Monday, 17'th Jan 2022
XPhyto Therapeutics Corp has announced the appointment of Drahoslav Zdarek as the company's head of sales, Europe. The company said Zdarek will focus on building out distribution, sales and marketing
Xphyto Therapeutics Corp. said it has made two key appointments to continue its focus on research, development and commercialization of its biosensor and diagnostic products, including for the detecti
